Humana Inc.

(New York Stock Exchange)
Back to all articles
Bullish +65

Humana's $2.8 bn BlackRock deal follows Medicare Advantage ratings recovery

Acquisition Business restructuring AI-generated analysis

🀝 Humana partners with BlackRock for a $2.8 billion restructuring of CenterWell clinics, replacing WCAS to reduce liabilities and lower the cost of capital.

πŸ“‰ The new joint venture removes mandatory investor put options, providing Humana with greater financial flexibility and time to develop its clinic portfolio.

⭐ Humana's Medicare Advantage quality ratings have rebounded sharply, with 95% of members in four-star or higher contracts for 2027 compared to 20% previously.

πŸ’° The rating recovery could unlock approximately $4.8 billion in federal bonus payments and an additional $3.6 billion in increased government payments by 2028.

πŸ“ˆ Humana shares surged roughly 15% following the ratings announcement, closing at $432.20 on October 15.

πŸ₯ CenterWell plans to deploy additional capital over the next two years to support existing clinics and establish new locations through acquisitions.

βš–οΈ S&P Global Ratings affirmed Humana's BBB issuer credit rating but maintained a negative outlook due to uncertainty about restoring operating margins.

🎯 Humana targets adjusted earnings of at least $9.00 per share for 2026, maintaining its previous guidance despite the restructuring impact on GAAP earnings.

Bullish Signals
  • Humana's Medicare Advantage quality ratings have recovered dramatically to 95% four-star or higher enrollment in 2027, significantly exceeding industry benchmarks and J.P. Morgan expectations.
  • The improved ratings position Humana to receive an estimated $4.8 billion in federal bonus payments starting in 2028, alongside an additional $3.6 billion in increased government payments year-over-year.
  • The BlackRock transaction removes investor put options and reduces balance sheet liabilities, lowering the cost of capital and providing flexibility to expand the CenterWell clinic network.
  • Humana shares surged approximately 15% on October 9 following the ratings announcement, reflecting strong investor confidence in the company's profitability recovery.
Risk Factors
  • The restructuring creates a derivative liability due to minimum return protections for BlackRock, which will be measured at fair value and could affect reported GAAP earnings.
  • Analysts caution that the ultimate earnings contribution from higher Medicare Advantage payments depends on how much Humana reinvests in member benefits and provider agreements.
Full Analysis
Humana (NYSE: HUM) has agreed to a $2.8 billion transaction with BlackRock to restructure ownership of nearly 150 CenterWell Senior Primary Care clinics. This deal replaces Welsh, Carson, Anderson & Stowe as Humana's private equity partner, allowing the insurer to retain operational control while reducing balance sheet liabilities and deferring decisions on acquiring facilities outright. The agreement is expected to close in the fourth quarter of 2026, subject to regulatory approvals. The transaction significantly improves Humana's financial flexibility by removing investor put options that previously required capital outlays, thereby lowering its cost of capital. While a derivative liability remains due to minimum return protections for BlackRock, the restructuring supports Humana's strategy to expand its clinic portfolio through additional capital deployment and acquisitions over the next two years. Simultaneously, Humana has recovered from recent declines in Medicare Advantage quality ratings, with approximately 95% of its members now enrolled in contracts rated four stars or higher for 2027. This recovery positions the company to receive substantial government bonus payments starting in 2028, estimated at $4.8 billion by Evercore ISI and an additional $3.6 billion in increased payments by S&P Global Ratings.